circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3

BACKGROUND: Docetaxel (DTX) is the most widely prescribed first-line chemotherapy for advanced prostate cancer (PCa). Unfortunately, DTX resistance invariably emerges, leading to worse prognosis of PCa. Growing evidence has shown that circRNAs had complex spatiotemporal specificity during the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Haoli, Qin, Haixiang, Yang, Lei, Chen, Mengxia, Yang, Yang, Zhang, Wenlong, Hao, Jiange, Lu, Qun, Shi, Jingyan, Zhuang, Junlong, Qiu, Xuefeng, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277795/
https://www.ncbi.nlm.nih.gov/pubmed/35831872
http://dx.doi.org/10.1186/s40364-022-00393-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277795/
https://www.ncbi.nlm.nih.gov/pubmed/35831872
http://dx.doi.org/10.1186/s40364-022-00393-1

Ejemplares similares